Vitiligo: Auto-immunity and immune responses

International Journal of Dermatology

Volumn 45, Issue 5, 2006, Pages 583-590

  Sehgal, Virendra N ^a,b,c   Srivastava, Govind ^a,b  

^a Sehgal Nursing Home   (India)

^b Behl Skin Institute   (India)

^c NONE   (India)

Author keywords

[No Author keywords available]

Indexed keywords

CATALASE; DIPEPTIDYL CARBOXYPEPTIDASE; HLA A ANTIGEN; HLA A2 ANTIGEN; HLA A3 ANTIGEN; HLA B ANTIGEN; HLA B27 ANTIGEN; HLA DQ ANTIGEN; HLA DR1 ANTIGEN; HLA DR3 ANTIGEN; HLA DR4 ANTIGEN; HLA DR7 ANTIGEN; IMMUNOGLOBULIN G ANTIBODY; IMMUNOSUPPRESSIVE AGENT; MEMBRANE COFACTOR PROTEIN;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIBODY DETECTION; AUTOIMMUNITY; CELLULAR IMMUNITY; COMPLEMENT ACTIVATION; DISEASE COURSE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; HEREDITY; HUMAN; IMMUNOGENICITY; IMMUNOPATHOGENESIS; IMMUNOSUPPRESSIVE TREATMENT; KERATINOCYTE; MELANOCYTE; MULTIFACTORIAL INHERITANCE; NATURAL KILLER CELL; NONHUMAN; PREVALENCE; REVIEW; T LYMPHOCYTE; VITILIGO;

AUTOIMMUNE DISEASES; DISEASE SUSCEPTIBILITY; HUMANS; VITILIGO;

EID: 33646189641     PISSN: 00119059     EISSN: 13654632     Source Type: Journal    
DOI: 10.1111/j.1365-4632.2005.02651.x     Document Type: Review

References (148)

1. Lerner A. Vitiligo. J Invest Dermatol 1959; 32: 285-310.
2. Howitz J, Brodthage H, Schwartz M, et al. Prevalence of vitiligo- epidemiological survey on the isle of Bornholm, Denmark. Arch Dermatol 1977; 113: 47-52.
3. Kovacs SD. Vitiligo. J Am Acad Dermatol 1998; 38: 647-666.
4. Handa S, Dogra S. Epidemiology of childhood vitiligo - a study of 625 patients from North-India. Pediator Dermatol 2003; 20: 207-210.
5. Herane MI. Vitiligo and leukoderma in children. Clin Dermatol 2003; 21: 283-295.
6. Ortonne JP, Mosher DB, Fitzpatrick TB. Vitiligo and the hypomelanosis of hair and skin. New York: Plenum Medical Book Company, 1983: 172-176.
7. Penkus H. Vitiligo -what is it? J Invest Dermatol 1959; 32: 281-284.
8. Srivastava G. Vitiligo - Introduction. Asian Clinic Dermatol 1994; 1: 1-5.
9. Barnes L. Vitiligo and Vogt-Koyanagi - Harada syndrome. Dermatol Clin 1988; 6: 229-239.
10. Njoo MD, Weskrhof W. Vitiligo, pathogenesis and treatment. Am J Clin Dermatol 2001; 2: 167-168.
11. Sehgal VN, Dube B. Secretary state in vitiligo. Dermatologica 1969; 138: 89-92.
12. Bhawan J, Bhutani LK. Keratinocyte damage in vitiligo. J Cutan Pathol 1983; 10: 207-212.
13. Iynger B, Misra RS. Neural differentiation of melanocytes in vitiliginous skin. Acta Anat (Basel) 1988; 133: 62-65.
14. Lee Poole LC, Das PK, Wijngard RM, et al. Review of the etio-pathologic mechanism of vitiligo - a convergence theory. Exp Dermatol 1993; 2: 145-158.
15. Rawles ME. Origin of melanophore and their role in development of color pattern in vertebrates. Physiol Rev 1948; 28: 382-408.
16. Lerner AB, Norland JJ. The loss of pigment in skin, hair and eyes. J Dermatol (Tokyo) 1978; 5: 1-8.
17. Tababa OA, Owolabi MO, Osotimehin BO. Auto immune diseases in a Nigerian woman. West Afr J Med 2003; 22: 361-363.
18. Norland JJ. The significance of de-pigmentation. Pigm cell Res 1992; 2: 237-241.
19. Smyth JR Jr, McNeil M. Alopecia areata and universalis in the Smyth chicken mode for spontaneous vitiligo. J Invest Dermatol Sym Proe 1999; 4: 211-215.
20. Belterle C, Caretto A, DeZio A, et al. Incidence and significance specific autoimmune disorders in patients with vitiligo. Dermatologica 1985; 171: 419-423.
21. Belterle C, Deeprete G, Preserico A, et al. Auto-antibodies in vitiligo. Arch Dermatol 1976; 112: 1328-1330.
22. Burns-Cox C, Pearson J. Addison's diseases, vitiligo and multiple auto-antibodies. Postgr Med J 1972; 48: 115-117.
23. Fields J, Fragola L, Hadley T. Hypo-parathyroidism, candidiasis, alopecia and vitiligo. Arch Dermatol 1971; 103: 687-690.
24. Fisher M, Fitzpatrick T. Candidiasis, vitiligo, additions disease and hypoparathyroidism. Arch Dermatol 1970; 102: 110-112.
25. Koga M, Tango T. Clinical features of type A and type B vitiligo. Br J Dermatol 1988; 118: 223-228.
26. Forcier R, McJntyre O, Frey W. Auto-immunity and multiple endocrine abnormalities. Arch Inter Med 1972; 129: 638-641.
27. Cunliffe W, Hall R, Newell J, et al. Vitiligo, thyroid disease and auto-immunity. Br J Dermatol 1968; 80: 135-139.
28. Shellreuter KU, Lenke R, Brandt O, et al. Vitiligo and the disease - co-existence or true association? Dermatology 1994; 188: 269-275.
29. Koshiyama H, Ito M, Yoshinami N, et al. Two cases of asymptomatic adrenocortical insufficiency with auto-immune thyroid disease. Endoer J 1994; 41: 373-378.
30. Allisan J, Curtis A. Vitiligo and pernicious anaemia. Arch Dermatol 1955; 72: 407-409.
31. Grunnel I, Hawitz J. Vitiligo and pernicious anaemia. Arch Dermatol 1970; 101: 82-85.
32. Dawber R. Integumentary association of pernicious anaemia. Br J Dermatol 1969; 82: 221-222.
33. Harrakahi MSE. Pernicious anaemia in Arabs. Blood Cells Mol Dis 1996; 22: 98-103.
34. Dawber R. Vitiligo in mature onset diabetes mellitus. Br J Dermatol 1968; 80: 275-278.
35. Husebye ES, Gebre-Melhin G, Tuomi T, et al. Auto-antibodies against aromatic amino and decarboxylase auto-immune polyendocrine syndrome type I. J Clin Endocrinal Metabol 1997; 82: 147-150.
36. Sharma VK, Dawn G, Kumar B. Profile of alopecia areata in Northern India. Int J Dermatol 1996; 35: 22-27.
37. Sharma VK, Kumar B, Dawn G. A clinical study of childhood alopecia areata in Chandigarh, India. Pediator Dermatol 1996; 13: 372-377.
38. Cecchi R, Giomi A, Tua F, et al. PRP, lichen planus, alopecia universalis and vitiligo in a patient of chronic viral hepatitis - C. Dermatology, 1994;188: 239-240.
39. Dunlop D. Eighty six cases of Addison's disease. Br Med J 1963; 2: 887-891.
40. Meecham J, Jones E. Addison's disease and Addisonian anemia. Lan Et 1967; 1: 535-538.
41. Bystran J. Serum antibodies in vitiligo patients. Clin Dermatol 1989; 7: 136-145.
42. Norlund JJ, Majundar PP. Recent investigation and vitiligo vulgaris. Dermatol Clin 1997; 15: 69-78.
43. Okada T, Sakamoto T, Ishibaslin T, et al. Vitiligo in Vogt-Kyanagi Hrada disease. Gracres Arch Clin Exp Ophthalmol 1996; 234: 359-363.
44. Okamoto T, Irie RF, Fujii S, et al. Anti-tyrosinase releted protein-2 immune response in vitiligo patients and helanoma patients recurring active specific immuno therapy. J Invest Dermatol 1998; 111: 1034-1039.
45. Merimsky O, Shoefeld Y, Fisherman P. The clinical significance antity-rosinase antibodies in melanoma and related hypo-pigmentary disorders. Clin Rev Allergis Dimmunol 1998; 16: 227-236.
46. Hann SK, Shin HK, Park SH, et al. Detection of antibodies to melanocytes in vitiligo by western immunoblotting. Yonsel Med J 1996; 37: 365-370.
47. Mandry RC, Qrtiz LJ, Lugo-somolinos A, et al. Organ-specific auto-antibodies in vitiligo patients and their relatives. Int J Dermatol 1996; 35: 18-21.
48. Mayunder P, Norlund J, Nath S. Pattern of familial aggregation of vitiligo. Arch Dermatol 1993; 129: 994-998.
49. Venkatraman MN, White AG, Leeny WA, et al. HLA antigens in Omani patients with vitiligo. Clin Exp Dermatol 1995; 20: 35-37.
50. AL-fouzan A, Al-Arbash M, Fonad F, et al. Study of HLA class I/II and T-lymphocyte subset in K uwaiti vitiligo patients. Eur J Immunogint 1995; 22: 209-213.
51. Hafez M, Sharf L, Abdel-Nabi S. The genetics of vitiligo. Acta Derm Venereal (Stockh) 1983; 63: 249-251.
52. Nath SK, Majumdar PP, Norland JJ. Genetic epidemiology of vitiligo-multilocus recessivity crossvali-dated. Am J Hum Genet 1994; 55: 981-990.
53. Das S, Majundar P, Chakraborty R, et al. Studies and vitiligo - epidemiological profile in Calcutta, India. Genet Epidemiol 1985; 2: 71-78.
54. Majundar P, Lic DAS. A Genetical model for vitiligo. Am J Human Genetic 1988; 43: 19-125.
55. Merelender J, Rywlen J. Hereditary of acquired vitiligo. Acta Derm Venereol (Stockh) 1940; 21: 583-585.
56. Sehgal VN. A clinical evaluation of 202 cases of vitiligo. Cutis 1974; 14: 439-445.
57. Behl PN. Vitiligo. In: Behl PN, Aggarwal A, Srivastava G, eds. Practice of Dermatology, 9th edn. New Delhi, India: CBS Publishers, 2003: 235-239.
58. Siemens HW. Die Zuvillings pathologie der vitiligo. Acta Genet Med Gemelol (Roman) 1953; 2: 118-124.
59. Mohar J. Vitiligo in a pair of mono-ovular twins. Acta Genet Stat Med 1951; 2: 252-255.
60. Jin SY, Park MH, Li GZ, et al. Association of angiotensin converting enzyme gene I/D polymorphism of vitiligo in Korean population. Pigment Cell Res 2004; 17: 84-86.
61. Spritz RA, Gowan K, Bennett DC, et al. Novel vitiligo susceptibility loci on chromosome 7 (AIS2) and 8 (AIS3) confirmation of SLEVI on chromosome 17, and their roles in an autoimmune diathesis. Am J Hum Genet 2004; 74: 188-191.
62. Lowerstein EJ, Kim KH, Click SA. Turner's syndrome in dermatology. J Am Acad Dermatol 2004; 50: 767-776.
63. Metzker A, Zamir R, Gazit E, et al. Vitiligo and HLA system. Dermatologica 1980; 160: 100-105.
64. Foley L, Lowe N, Misheloff E, et al. Association of HLA- DR4 with vitiligo. J Am Acad Dermatol 1983; 8: 38-40.
65. Dunston G, Halder R. Vitiligo in associated with HLA-DR4 in black patients. Arch Dermatol 1990; 126: 56-60.
66. Poloy Tibor L, Kramer J, et al. HLA-DR1 is associated with vitiligo. Immunol Lett 1991; 27: 59-62.
67. Finico O, Cuccia M, Matinetti M, et al. Age of onset in vitiligo- relationship with HLA-serotypes. Clin Genet 1991; 39: 48-54.
68. Lorini R, Orecchia G, Martinetti M, et al. Auto immunity in vitiligo -relationship with HLA. Gm and Km polymorphisim. Autoimmunity 1992; 11: 255-260.
69. Orecchia G, Perfeti P, Malagoli F, et al. Vitiligo is associated with a significant increase in HLA-A30, CW6 and DQW3 and a decrease in C4AQ o in northern Italian patients. Dermatology, 1992; 185: 123-127.
70. Vennekar G, Westerhof W, Devries I, et al. Molecular heterogeneity of C4 and its genes in vitiligo. J Invest Dermatol 1992; 99: 853-858.
71. Buc M, Busova B, Hegyi E, et al. Vitiligo is associated with HLA-A3, and HLA-DW7 in Slovak populations. Folia Biologica, 1996; 42: 23-25.
72. Naughtom GK, Eisinger M, Bystran JC. Detection of antibodies to melanocytes in vitiligo by specific immuno precipitation. J Invest Dermatol 1983; 81: 540-542.
73. Harning R, Cui J, Bystrian JC. Rebtion between the incidence and level of pigment cell antibodies and disease activity in vitiligo. J Invest Dermatol 1991; 97: 1078-1080.
74. Hertz KC, Gaze LA, Kirkpatrick CH, et al. Autoimmune vitiligo - detection of antibodies to melanin producing cell. N Engl J Med 1977; 297: 634-637.
75. Naughton GK, Eisnger M, Bystryn JC. Antibodies to normal human melanocytes in vitiligo. J Exp Med 1983; 158: 246-251.
76. Cui J, Harning R, Hemm M, et al. Identification of pigment cell antigens defined by vitiligo antibodies. J Invest Dermatol 1992; 98: 162-165.
77. Norris DA, Kissinger RM, Naughton GM, et al. Evidence for immunologic mechanisms in human vitiligo. J Invest Dermatol 1988; 90: 783-789.
78. Venneker GT, Puri N, Westerhof W, et al. Membrane co-factor protein (MCP) and decay acceleration factor are grossly reduced in vitiligo lesions. Pigment Cell Res 1992; 5: 1998.
79. Howanitz N, Norland J, Lermer A. Antibodies to melanocytes. Arch Dermatol 1981; 117: 705-708.
80. Norris A, Todd C, Grahant XX, et al. The expression of the C-kit receptor by epidermal melanocytes may be reduced vitiligo. Br J Dermatol 1996; 134: 299-306.
81. Puri N, Moginder M, Ramaih A. Growth defects of melanocytes in culture from vitiligo subjects are spontaneously corrected in vivo in re-pigmented subjects, and can partially corrected by addition of Fibroblast derived growth factor in vitro. Arch Dermatol Res 1989; 281: 178-184.
82. Morris DA, Horikawa T, Morelli JG. Melanocytes destruction and repopulation in vitiligo. Pigments Cell Res 1994; 7: 193-203.
83. Hann SK, Kin HI, Im S, et al. The change of melanocytes cytotoxicity after systemic steroid treatment in vitiligo patients. J Dermatol Sci 1993; 6: 201-205.
84. Sehgal VN, Dube B. ABO groups and vitiligo. J Med Genet 1968; 5: 308-309.
85. Sehgal VN, Dube B. Secretion of blood group specific substances in saliva of vitiligo patients. Br J Dermatol 1976; 79: 704-705.
86. Aronson P, Hashimoto K. Association of IgA anti-melanoma antibodies in the area of vitiligo patients with active disease. J Invest Dermatol 1987; 8: 475-477.
87. Bic C, Suender J, Soltani K, et al. Anti-melanocytes antibodies and vitiligo. J Invest Dermatol 1989; 92: 403-408.
88. Yu J, Kao C, Yu C. Co-existence and relationship of anti-keratinocyte and anti-melanocytes antibodies in patients with non-segmental type vitiligo. J Invest Dermatol 1993; 100: 823-828.
89. Naughton G, Reggiardo D, Bystryn J. Correlation between vitiligo antibodies and extent of de-pigmentation in vitiligo. J Am Acad Dermatol 1986; 15: 978-981.
90. Baharav E, Merimski O, Shoefeld Y, et al. Tyrosinase as an auto-antigen in patients with vitiligo. Clin Exp Immunol 1996; 105: 84-88.
91. Merimsky O, Baharav E, Shoefeld Y, et al. Anti-tyrosinase antibodies in malignant melanoma. Cancer Immunol Dermo Another 1996; 42: 297-302.
92. Hammer H. Lymphocytes transformation test in sympathetic ophthalmitis and the Vogt Koyanagi-Harada syndrome. Br J Optithalm 1971; 55: 850-852.
93. Hammer H. Cellular hypersensitivity to uveal pigment conformed by leucocyte migration test in sympathetic ophthalmitis and Vogt-Koyanagi Harada syndrome. Br J Ophiliam 1974; 59: 773-776.
94. Wojdani A, Grinme P, Loch L, et al. Detection of anti-benzene ring antibodies in patients with vitiligo. J Invest Dermatol 1992; 92: 644-648.
95. Xiap XX, Geoghegan W, Jordan R. Vitiligo antibodies - studies of sub class distribution and complement activation. I Invest Dermatol 1991; 96: 627-631.
96. Dal Pra C, Chen S, Betterle C, et al. Autoantibodies to human tryptophan hydroxylase and aromatic 1-amino acid decarboxylase. Eur J Endocrinol 2004; 150: 313-321.
97. Beisland C, Holsen DS. Vitiligo-an autoimmune side-effect of intravesical bacillus Calmette-Guerin instillation? Scand J Urol Nephrol 2004; 38: 182-183.
98. Horn TD, Abanni A. Analysis of the lymphocytic infiltrate in a case of vitiligo. Am J Histopathol 1997; 19: 400-402.
99. Mozzamica N, Frigerio U, Fwizi AF, et al. T-cell subpopulations in vitiligo - a chronological study. J Am Acad Dermatol 1990; 22: 223-230.
100. 25+ of T helper cells in non-segmental vitiligo. J Dermatol 2002; 29: 68-73.
101. 45RA+ T-cells subset, and evidence for peripheral T-cell activation. Int J Dermatol 1992; 31: 321-326.
102. Sehgal VN, Dube B. Secretary state - a positive prognostic sign in vitiligo. Dermatologica 1969; 139: 168-171.
103. Le Poole JC, den-Wizngaard RM, Westerhof W, et al. Presence of T-cells and macrophages in inflammatory vitiligo skin parallels melanocytes disappearance. Am J Pathol 1996; 148: 1219-1228.
104. Antony FC, Marsden RA. Vitiligo in association with HIV infection. J Eur Acad Dermatol Venereol 2003; 17: 456-458.
105. Grimes P, Ghoneum M, Stockton T, et al. T-cell profiles in vitiligo. J Am Acad Dermatol, 1986; 14: 196-199.
106. Holder R, Walters C, Jonson B, et al. Aberration of T-lymphocytes and natural killer cell in vitiligo. J Am Acad Dermatol 1986; 14: 733-738.
107. Soubiran P, Benzaken S, Bellet C, et al. Vitiligo T-cell subset unbalance as defined by monoclonal antibodies. Br J Dermatol 1985; 113: 124-127.
108. D'Amelio R, Frati C, Fattorossi A, et al. Peripheral T-cell subset imbalance in patients with vitiligo and their apparently healthy first degree relatives. Ann Allegy 1990; 65: 143-145.
109. Gross A, Tapia FJ, Mosca W, et al. Mononuclear cells sub-populations and infiltratory lymphocytes in erythema dyschromicum perstan and vitiligo. Histoid Histopathol 1987; 2: 277-283.
110. Zaman T, Begum S, Waheed M. In vitro assessment of T-lymphocytes functioning in vitiligo. Acta Derm Venereol (Stockh.) 1992; 72: 2667-2669.
111. Durham-Pierre DG, Walters CS, Halder RM, et al. Natural killer cell and lymphocytic-activated killer cell activity against melanocytes in vitiligo. J Am Acad Dermatol 1995; 33: 26-30.
112. Le Poole IC, Wankowicz-Kalinska A, Van den Wijngaard RM, et al. Autoimmune aspects of de-pigmentation in vitiligo. J Invest Dermtol Symp Proc 2004; 9: 68-72.
113. Kano Y, Shiohara I, Nagashima M. Epidermal Langerhan's cells in various skin diseases (2) Langerhan's cells in vitiligo. J Dermatol (Tokyo) 1984; 11: 103-110.
114. Westerhof W, Groot I, Krieg SR, et al. Langerhan's cells subpopulation studies with OK T6 and HLA-DR monoclonal antibodies in vitiligo patients treated with oral phenylalanine loading and UVA irradiation. Acta Derm Venereol 1986; 66: 259-262.
115. Palkowski MR, Norlund ML, Rheins LA, et al. Langerhan's cells in hair follicles of the de-pigmentary C57, B1/Ler-vit moue: A model for human skin. Arch Dermatol 1987; 123: 1022-1028.
116. Kao CH, Yu HS. Depletion and repopulation of Langerhan's cells in non-segmental type vitiligo. J Dermatol (Tokyo) 1990; 17: 287-296.
117. Bose SK. Probable mechanism of loss of Markel cells in completely de-pigmented skin of stable vitiligo. J Dermatol (Tokyo) 1994; 21: 725-728.
118. Bose SK. Absence of Markel cells in lesional skin of vitiligo (corrected). Int J Dermaol 1994; 33: 481-483.
119. Bose SK, Ortonne JP. Focal gaps in the basement membrane of involved skin of vitiligo. Are they normal? J Dermatol (Tokyo) 1994; 21: 119-152.
120. Hann SK, Park TK, Lee KG, et al. Epidermal changes in active vitiligo. J Dermatol (Tokyo) 1992; 19: 217-222.
121. Moellmann G. Keratinocyte in vitiligo. J Invest Dermatol, 1992; 99: 665.
122. Philips J, Gawkrodger DJ, Caddy CM, et al. Keratocyte suppresses TRP-1 expression and reduce cell number of co-cultured melanocytes. Pigment Cell Res 2001; 14: 116-125.
123. Hamada T, Sakurane HF, Saito T. Behavior of pigment cells on lesions of the pigmented versus vitiligo. J Dermatol (Tokyo) 1979; 6: 143-152.
124. Lernier AB. Repopulation of pigment cells in patients with vitiligo. Arch Dermatol 1988; 124: 1701-1702.
125. Olssy RE, Liu YY, Medrano EE, et al. Structural aberration of the rough endoplasmic reticulum and melanosome compartmentalization in long term cultures of melanocytes from vitiligo patients. J Invest Dermatol 1991; 97: 395-404.
126. Im S, Hann SK, Park YK, et al. Culture of melanocytes obtained from normal and vitiligo subjects. Yonsei Med J 1992; 33: 344-350.
127. Jee SH, Kuoy F, Wu YC, et al. Growth of human melanocytes from suction blisters of localized vitiligo patients and from foreskins of newborn and adult by modified culture medium. J Formos Med Assoc 1993; 92: 7-14.
128. Le Poole TC, Van den Vigngaard RH, Westerhof W, et al. Presence or absence of melanocytes in vitiligo lesions - an immuno-histo-chemical investigation. J Invst Dermatol 1993; 100: 816-822.
129. Arrunategul A, Arroyo C, Garcia L, et al. Melanocytes reservoir in vitiligo. Int J Dermatol 1994; 33: 484-487.
130. Ozdemir M, Xillar G, Wolf R, et al. Increased basic fibroblast growth factor levels in serum and blister fluid from patients with vitiligo. Acta Derm Venereol 2000; 80: 438-439.
131. Tobin DJ, Swanson NN, Pittelkow MR, et al. Melanocytes are not absent in lesional skin of long duration vitiligo. J Pathol 2000; 191: 407-416.
132. Yu HS. Melanocyte destruction and re-pigmentation in vitiligo: A modal for nerve cell damage and re-growth. J Biomed Sci 2002; 9: 564-573.
133. Gauthier Y, Cario-Andre M, Lepreux S, et al. Melanocyte detachment after skin friction in non-lesional skin of patients with generalized vitiligo. Brit J Dermatol 2003; 148: 95-101.
134. Ortonne JP, Perrot H. Giant melanin granules in vitiligenous achromia with malignant melanoma. Arch Derm Venereol 1978; 58: 475-480.
135. Gokhale B, Mehta LN. Histopathology of the vitiligenous skin. Int J Dermatol 1983; 22: 477-480.
136. Le Poole IC, Das PK. Microscopic changes in vitiligo. Clin Dermatol 1997; 15: 863-873.
137. Montes LF, Abulafia J, Wilborn WH, et al. Value of histopathology in vitiligo. Int J Dermatol 2003; 42: 57-61.
138. Morohashi M, Hashimoto K, Goodman TFJ. Ultra-structural studies of vitiligo, Vogt-Koyanagi-Harada disease, and incontinentia pigmenti achromicans. Arch Dermatol 1977; 113: 755-766.
139. Ishii M, Hamada T. Ultra-structural studies of vitiligo with inflammatory to raised borders. J Dermatol (Tokyo) 1981; 8: 313-322.
140. Galadari E, Mehregan AH, Hashimoto K. Ultra-structural study of vitiligo. Int J Dermatol 1993; 32: 269-271.
141. Panuncio AL, Vignale R. Ultra-structural studies in stable vitiligo. Am J Histopathol 2003; 25: 16-20.
142. Cui J, Chen D, Misfeldt ML, et al. Anti-melanoma antibodies in swine with spontaneously regressing melanoma. Pigment Cell Res 1995; 8: 60-63.
143. Austin L, Boissy R, Jacobson B, et al. The detection of melanocytes antibodies in the Smyth chicken model for vitiligo. Clin Immunol Immunopathol 1992; 64: 112-120.
144. Sreekumar GP, Eft GF, Smyth Jr. 5-azacytidine treatment induces autoimmune vitiligo in parental control strains of the Symth line chicken model for autoimmune vitiligO. Clin Immunol Immunopathol 1996; 81: 136-144.
145. Naughton G, Mahaffey M, Bystryn J. Anti-bodies to surface antigens of pigmented cells in animals with vitiligo. Proc Soc Exp Biol Medical 1986; 181: 423-426.
146. Erf GF, Smyth JR Jr. Alteration in blood leucocyte populations in Smyth line chickens with autoimmune vitiligo. Poultry Sci 1996; 75: 351-356.
147. Erf GF, Trejo-Steal I, Av Smyth JR. T-cells in regenerating feather of Smyth line chickens with vitiligo. Clin Immunol Immunopathol 1995; 76: 120-126.
148. Austin L, Boissy R, Jacobson B, et al. The detection of melanocytes auto-antibodies in the Smyth line chickens model for vitiligo. Clin Immunol Dermopathol 1992; 64: 12-120.